Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in

D R Beidler1, Y C Cheng

  • 1Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.

Molecular Pharmacology
|May 1, 1995
PubMed
Summary

Camptothecin (CPT) increases DNA breaks by inhibiting topoisomerase I (TOP1). However, prolonged CPT exposure reduces TOP1 levels, potentially causing resistance to its toxic effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the Effectiveness of the Introduction of Automated Physiological Monitoring Devices.

Studies in health technology and informatics·2021
Same author

Study of expiratory droplet dispersion and transport using a new Eulerian modeling approach.

Atmospheric environment (Oxford, England : 1994)·2020
Same author

[Investigation of the cognition and behavior on drug safety in Beijing middle school students].

Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences·2017
Same author

[Clinical observation on human alpha glucosidase in treatment of five patients with glycogen storage disease Ⅱ].

Zhonghua er ke za zhi = Chinese journal of pediatrics·2016
Same author

Structure-based discovery and development of natural products as Type II JAK2 inhibitors for the treatment of hepatitis C.

Hong Kong medical journal = Xianggang yi xue za zhi·2016
Same author

Heritability of young- and old-onset ischaemic stroke.

European journal of neurology·2015

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Camptothecin (CPT) is a potent anti-cancer agent that functions by stabilizing DNA-topoisomerase I (TOP1) covalent complexes, leading to protein-linked DNA breaks (PLDB).
  • CPT's efficacy is influenced by the duration of exposure and the cellular levels of TOP1, as PLDB formation is reversible and CPT toxicity requires replication fork progression.

Purpose of the Study:

  • To investigate the dynamic effects of CPT exposure on TOP1 levels and PLDB formation over time in human KB cells.
  • To elucidate the mechanisms underlying changes in TOP1 protein levels during CPT treatment and their impact on CPT-induced DNA damage.

Main Methods:

  • Utilized an in vivo KCl-SDS co-precipitation assay to quantify PLDB formation.
  • Employed immunoblot analysis to assess TOP1 protein levels and RNA analysis to examine TOP1 mRNA expression.

Related Experiment Videos

  • Conducted clonogenic assays to evaluate CPT's cytotoxic effects under varying exposure conditions.

    • Main Results:

    • CPT exposure initially increased PLDB in a concentration-dependent manner, peaking at 5 microM.
    • Prolonged CPT incubation led to a concentration- and time-dependent decrease in PLDB, with rapid loss observed within 6 hours.
    • Immunoblotting revealed a significant reduction in TOP1 protein levels upon CPT exposure, without corresponding changes in TOP1 mRNA, suggesting post-transcriptional regulation.
    • CPT treatment specifically reduced TOP1 levels, leaving actin and tubulin unaffected.
    • Clonogenic assays showed a modest but significant decrease in CPT toxicity with extended exposure.

    Conclusions:

    • CPT-induced reduction in TOP1 protein levels occurs via a post-transcriptional mechanism.
    • This down-regulation of TOP1 represents a potential cellular resistance mechanism against CPT toxicity by limiting PLDB formation.
    • Understanding these dynamic changes in TOP1 is crucial for optimizing CPT-based cancer therapies.